• Joanna Rhodes, Anthony Mato, and Jeff P Sharman.
• University of Pennsylvania, 3400 Civic Center Blvd, PCAM 12 South, Philadelphia, PA, 19104, USA. Joanna.rhodes@uphs.upenn.edu.
• Curr Oncol Rep. 2018 Apr 11; 20 (6): 49.

Purpose ReviewB cell signaling agents, including ibrutinib, idelalisib, and the BCL-2 inhibitor venetoclax have become an integral part of therapy for patients with non-Hodgkin's lymphomas. The toxicity profiles of these medications is distinct from chemoimmunotherapy. Here, we will review the mechanism of action of these drugs, their efficacy, and toxicity management.Recent FindingsIbrutinib use is associated with increased risk of atrial fibrillation and bleeding which can be managed using dose interruptions and modifications. Patients on idelalisib require close clinical and frequent laboratory monitoring, particularly of liver function tests to ensure there are no serious adverse events. Monitoring for infections is important in patients on both idelalisib and ibrutinib. Venetoclax requires close clinical and laboratory monitoring to prevent significant tumor lysis. Targeted B cell receptor therapies each have unique side effect profiles which require careful clinical monitoring. As we continue to use these therapies, optimal management strategies will continue to be elucidated.

48 keywords...

hide…